Results 1 to 10 of about 789,124 (302)

Deletion within the Src homology domain 3 of Bruton's tyrosine kinase resulting in X-linked agammaglobulinemia (XLA). [PDF]

Journal of Experimental Medicine, 1994
The gene responsible for X-linked agammaglobulinemia (XLA) has been recently identified to code for a cytoplasmic tyrosine kinase (Bruton's agammaglobulinemia tyrosine kinase, BTK), required for normal B cell development. BTK, like many other cytoplasmic
Mauno Vihinen, Sau-Ping Kwan, Lennart Nilsson   +2 more
exaly   +3 more sources

Second‐line therapy with first‐ or second‐generation tyrosine kinase inhibitors in EGFR‐mutated non‐small cell lung cancer patients with T790M‐negative or unidentified mutation

Thoracic Cancer, 2021
Background T790M mutation causes resistance to tyrosine kinase inhibitors (TKIs) in approximately 49% of patients with epidermal growth receptor‐mutant non‐small cell lung cancer (NSCLC).
Tadashi Nishimura, Tomohito Okano, Masahiro Naito, Soichi Iwanaka, Ayaka Ohiwa, Yasumasa Sakakura, Taro Yasuma, Hajime Fujimoto, Corina N. D'Alessandro‐Gabazza, Yasuhiro Oomoto, Tetsu Kobayashi, Esteban C. Gabazza, Hidenori Ibata   +12 more
doaj   +1 more source

The tyrosine kinase Csk dimerizes through Its SH3 domain. [PDF]

PLoS ONE, 2009
The Src family kinases possess two sites of tyrosine phosphorylation that are critical to the regulation of kinase activity. Autophosphorylation on an activation loop tyrosine residue (Tyr 416 in commonly used chicken c-Src numbering) increases catalytic
Nicholas M Levinson, Patrick R Visperas, John Kuriyan   +2 more
doaj   +1 more source

Treatment of anaplastic lymphoma kinase-positive lung adenocarcinoma with pemetrexed and carboplatin after crizotinib failure and significant liver dysfunction; a case report

Cancer Treatment and Research Communications, 2021
Tyrosine kinase inhibitors are the first-line treatment for Anaplastic Lymphoma Kinase-positive lung adenocarcinomas. However, chemotherapy is still an option in patients who are unresponsive or intolerant of tyrosine kinase inhibitors.
Oranus Mohammadi, Kayla Haines, Mohammad Jahanzeb   +2 more
doaj   +1 more source

Safety and Efficacy of Tyrosine Kinase Inhibitors in Immune Thrombocytopenic Purpura: A Systematic Review of Clinical Trials

Journal of Xenobiotics, 2023
Immune thrombocytopenic purpura (ITP) is an acquired antibody or cell-mediated platelet damage or decreased platelet production. Steroids, IV immunoglobulins (IVIG), and Rho-anti-D antibodies are the commonly used initial treatments for ITP.
Muhammad Ashar Ali, Muhammad Yasir Anwar, Wajeeha Aiman, Gurneel Dhanesar, Zainab Omar, Mohammad Hamza, Maha Zafar, Harish Kumar Rengarajan, Michael Maroules   +8 more
doaj   +1 more source

Anexelekto/MER tyrosine kinase inhibitor ONO-7475 arrests growth and kills FMS-like tyrosine kinase 3-internal tandem duplication mutant acute myeloid leukemia cells by diverse mechanisms

Haematologica, 2017
Nearly one-third of patients with acute myeloid leukemia have FMS-like tyrosine kinase 3 mutations and thus have poor survival prospects. Receptor tyrosine kinase anexelekto is critical for FMS-like tyrosine kinase 3 signaling and participates in FMS ...
Peter P. Ruvolo, Huaxian Ma, Vivian R. Ruvolo, Xiaorui Zhang, Hong Mu, Wendy Schober, Ivonne Hernandez, Miguel Gallardo, Joseph D. Khoury, Jorge Cortes, Michael Andreeff, Sean M. Post   +11 more
doaj   +1 more source

Analysis of Tumor Heterogeneity Through AXL Activation in Primary Resistance to EGFR Tyrosine Kinase Inhibitors

JTO Clinical and Research Reports, 2023
Introduction: EGFR tyrosine kinase inhibitors are standard therapeutic agents for patients with advanced NSCLC harboring EGFR mutations. Nevertheless, some patients exhibit primary resistance to EGFR tyrosine kinase inhibitors in the first-line treatment
Ryota Nakamura, MD, Hiroyuki Fujii, MD, Tadaaki Yamada, MD, PhD, Yohei Matsui, MD, Takeshi Yaoi, MS, Mizuki Honda, MD, Noriyuki Tanaka, MD, PhD, Aya Miyagawa-Hayashino, MD, PhD, Akihiro Yoshimura, MD, PhD, Kenji Morimoto, MD, PhD, Masahiro Iwasaku, MD, PhD, Shinsaku Tokuda, MD, PhD, Young Hak Kim, MD, PhD, Eiichi Konishi, MD, PhD, Kyoko Itoh, MD, PhD, Koichi Takayama, MD, PhD   +15 more
doaj   +1 more source

EGF regulates tyrosine phosphorylation and membrane-translocation of the scaffold protein Tks5 [PDF]

, 2013
Background: Tks5/FISH is a scaffold protein comprising of five SH3 domains and one PX domain. Tks5 is a substrate of the tyrosine kinase Src and is required for the organization of podosomes/invadopodia implicated in invasion of tumor cells.
Buday, László, Bőgel, Gábor, Fekete, Anna, Geiszt, Miklós, Pesti, Szabolcs, Péterfi, Zalán   +5 more
core   +1 more source

A chemical genetic approach reveals distinct EphB signaling mechanisms during brain development. [PDF]

, 2012
EphB receptor tyrosine kinases control multiple steps in nervous system development. However, it remains unclear whether EphBs regulate these different developmental processes directly or indirectly.
Ataman, Bulent, Bloodgood, Brenda L, Cowan, Christopher W, Greenberg, Michael E, Ho, Hsin-Yi Henry, Malik, Athar N, Robichaux, Michael A, Rubin, Alex A, Sharma, Nikhil, Shokat, Kevan M, Soskis, Michael J, Zhang, Chao, Zieg, Janine   +12 more
core   +1 more source

QTC Changes Associated with Tyrosine Kinase Inhibitors in Cancer Patients

Pakistan Armed Forces Medical Journal, 2022
Objective: To look for QTc changes associated with Tyrosine Kinase inhibitors and factors related to these changes among patients suffering from cancer. Study Design: Comparative cross-sectional study.
Rahimullah Khattak, Riaz Ahmad, Muhammad Nadeem, Huma Amjad, Amjad Khan, Ibtisam .   +5 more
doaj   +1 more source